RESULTS FROM THE ELUCIDATE TRIAL Sudeep Tanwar 1 Walter Gregory 2 The ELUCIDATE Investigators 3 Peter Selby 4 William Rosenberg 5 , 1 Institute for Liver & Digestive Health, 2 Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, 3 UK Secondary Care Gastroenterologists and Hepatologists, 4 Leeds Institute of Molecular Medicine, University of Leeds, UK, 5 University College London Medical School Background: Biomarkers have been validated for the prediction of adverse events in chronic liver disease (CLD) patients with a diagnosis of cirrhosis
Exploring molecular mechanisms and biomarkers in COPD: an overview of current advancements and perspectives
This is higher than the recommended Nutrient Reference Value (NRV) because it is specifically designed to help recovery from B12 deficiency by increasing levels in those who are deficient
Case Rep Pediatr
Thymoquinone (TQ), a bioactive compound of Nigella sativa seeds, has emerged as a therapeutic candidate for various diseases due to its diverse pharmacological properties (11), including antioxidant, anti-inflammatory, antiviral, anticancer (12, 13), antibacterial (14, 15), immunomodulatory (16), anticoagulant (17), antipsychotic, anxiolytic, antidepressant (18), and anticonvulsant activities (19, 20)